Chaga Safety & Dosing
3 Cases
Three published case reports document kidney failure from sustained chaga mushroom consumption, ranging from 3 months to 5 years of daily use. All three involved oxalate crystal deposition in renal tubules, a risk driven by chaga's exceptionally high oxalate content.
Lee et al., J Korean Med Sci, 2020
14.2g/100g
oxalate measured in the chaga powder consumed by the end-stage renal disease patient (Lee et al., 2020)
3 of 3
cases involved dialysis; one recovered fully, one progressed to end-stage renal disease
No RCT
exists testing long-term safety of chaga supplementation in humans
Lee et al., J Korean Med Sci, 2020
View as image ↗Chaga (Inonotus obliquus) has a centuries-long history in folk medicine across Russia, Scandinavia, and East Asia. Modern research has documented anti-inflammatory, antioxidant, anticancer, and anti-diabetic properties in cell and animal studies. The same mushroom has now generated three published case reports of severe kidney damage from sustained consumption, spanning 3 months to roughly 5 years of daily use, all caused by the same mechanism: oxalate crystal deposition in renal tubules. Chaga contains exceptionally high concentrations of oxalic acid, and sustained consumption can deliver oxalate loads that overwhelm the kidneys' capacity to excrete them. One of those three patients progressed to end-stage renal disease, one was started on hemodialysis with no recovery reported, and the third recovered fully. No randomized controlled trial has tested long-term safety at any dose, and no toxicology study has tested chaga for kidney toxicity at all. The evidence for benefits and the evidence for risks come from fundamentally different study types, and that mismatch, rather than any single number, is what makes the safety question hard to answer. For the specific oxalate concern, see chaga side effects: oxalate risk and kidney concerns.
Key Takeaways
- A 72-year-old woman consuming 4-5 teaspoons of chaga powder daily for 6 months developed oxalate nephropathy requiring hemodialysis; renal biopsy confirmed calcium oxalate crystal deposits (Kikuchi et al., 2014)
- A 49-year-old man who took chaga powder for intractable atopic dermatitis developed end-stage renal disease; biopsy showed chronic tubulointerstitial nephritis with oxalate crystals, and his chaga measured 14.2 g oxalate per 100 g (Lee et al., 2020)
- A 69-year-old man taking 10-15 g of chaga powder plus 500 mg vitamin C daily for 3 months developed acute kidney injury presenting as nephrotic syndrome; his kidney function fully recovered within a month of dialysis and high-dose steroids (Kwon et al., 2022)
- No published toxicology study has tested chaga for kidney or liver toxicity. The animal work most often cited for safety (Mishra et al., 2012) was a 7-day colitis efficacy study that never measured renal endpoints
- No human randomized controlled trial has tested chaga safety at any dose over any duration
- Many North American "chaga" supplements are not chaga: Windsor et al. (2025) found starch-rich mycelium-on-fermented-grain products that are compositionally distinct from authentic wildcrafted chaga canker
The Oxalate Problem: Chaga's Unique Risk
Oxalic acid is found in many foods: spinach, rhubarb, beets, nuts, chocolate, and tea. The body excretes oxalate through the kidneys, where it binds calcium to form calcium oxalate crystals. In most people eating a normal diet, this process is manageable. Problems arise when oxalate intake chronically exceeds the kidneys' excretory capacity, causing crystals to accumulate in renal tubules, a condition called oxalate nephropathy.
Chaga contains oxalate concentrations far higher than any common dietary source. Lee et al. (2020) measured the leftover chaga powder consumed by their patient and found 14.2 grams of oxalate per 100 grams.[3] It is the only one of the three published cases in which the product the patient actually consumed was chemically analyzed. For comparison, standard food-composition references put spinach, one of the highest-oxalate foods in an ordinary diet, at roughly 0.6-0.9 grams per 100 grams. On that basis chaga is on the order of 15 to 25 times more oxalate-dense than spinach, gram for gram. A person consuming several grams of chaga powder daily could be delivering an oxalate load comparable to eating hundreds of grams of raw spinach every day, sustained over months or years.
The oxalate in chaga is not a contaminant or a variable that can be eliminated through preparation. It is an intrinsic component of the fungal biomass. Hot water extraction (chaga tea) may reduce oxalate concentration compared to consuming raw powder, because not all oxalate is water-soluble. But no study has systematically measured oxalate content across different preparation methods (tea, tincture, capsule, raw powder) to establish which method minimizes exposure.
Case 1: Kikuchi et al. (2014): The First Published Report
Kikuchi et al. (2014) described a 72-year-old Japanese woman who had been consuming 4-5 teaspoons of chaga mushroom powder daily for 6 months following a liver cancer diagnosis and hepatectomy.[2] Renal function progressively declined, and hemodialysis was initiated. Renal biopsy revealed extensive oxalate crystal deposits in the tubules, confirming the diagnosis of chaga-induced oxalate nephropathy.
This was the index case that alerted the medical community to chaga's oxalate risk. Several features of this case deserve attention: the patient was elderly (kidneys have less reserve capacity with age), had a recent major surgery (hepatectomy), and was likely using chaga as an alternative cancer treatment alongside other medications. Whether any of these comorbidities increased her susceptibility beyond what chaga alone would cause is unknown.
Case 2: Lee et al. (2020): End-Stage Renal Disease
Lee et al. (2020) reported a 49-year-old Korean man who developed end-stage renal disease after long-term chaga ingestion.[3] He was transferred to the hospital with ESRD, and review of his kidney biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits. His drug history revealed long-term chaga powder use taken for intractable atopic dermatitis, not for cancer. The authors obtained the remaining chaga powder and measured its oxalate content at 14.2 g per 100 g. From that they estimated his daily oxalate intake at roughly twice a usual diet for four years, rising to about five times a usual diet in the final year.
This case is the most informative of the three, for several reasons. The patient was younger than the Kikuchi case (49 vs. 72) and did not carry the same confounding comorbidities. The exposure window was long and quantified: five years of elevated oxalate intake, not a few months. And critically, the authors measured the actual product rather than inferring the dose, which is what makes the 14.2 g per 100 g figure the anchor number for this entire topic. The endpoint was also the worst of the three: ESRD is irreversible loss of kidney function requiring lifelong renal replacement therapy. The authors reviewed the literature and concluded that chaga consumption should be recognized as a potential cause of oxalate nephropathy and chronic kidney disease.
Lee et al. (2020) · Journal of Korean Medical Science
- Population
- One 49-year-old Korean man with end-stage renal disease, referred for evaluation
- Intervention
- Long-term daily chaga mushroom powder, taken for intractable atopic dermatitis
- Finding
- Kidney biopsy showed chronic tubulointerstitial nephritis with oxalate crystal deposits. The retained chaga powder measured 14.2 g oxalate per 100 g. Estimated daily oxalate intake was about 2x a usual diet for four years and about 5x in the final year.
narrow-scope A single case report. It establishes that this can happen and quantifies the exposure, but a case report cannot establish how often it happens or at what threshold.
Lee et al. (2020), J Korean Med Sci, 35(19):e122
Case 3: Kwon et al. (2022): Nephrotic Syndrome Presentation
Kwon et al. (2022) documented a 69-year-old man who developed acute kidney injury presenting as nephrotic syndrome (massive protein loss in urine), an unusual presentation for oxalate nephropathy that initially complicated the diagnosis.[1] He had been taking 10-15 grams of chaga mushroom powder per day, along with 500 mg of vitamin C per day, for the previous 3 months. Biopsy showed focal acute tubular injury with calcium oxalate crystal deposition in the tubules, plus interstitial fibrosis and tubular atrophy; electron microscopy showed effacement of podocyte foot processes. The diagnosis was acute oxalate nephropathy accompanied by minimal change disease.
Two details make this case distinct from the other two, and both cut against reading it as a simple "chaga causes kidney failure" data point.
The first is the vitamin C. Ascorbic acid is metabolized to oxalate in the body, and high-dose supplemental vitamin C is itself an established cause of oxalate nephropathy. This patient was taking a daily oxalate load from chaga and a daily precursor load from vitamin C. The two exposures are not separable in a single case, so chaga cannot be assigned sole responsibility here.
The second is the outcome. His kidney function did not improve with hydration and blood pressure control, so he was treated with hemodialysis and high-dose steroids (intravenous hydrocortisone 500 mg twice daily for 3 days, then oral prednisolone at 1 mg/kg). His kidney function recovered within one month, and the minimal change disease went into complete remission. Unlike the Kikuchi and Lee patients, this man got better.
That recovery matters for how the case series should be read. Three published cases is not three identical catastrophes. The nephrotic syndrome presentation also carries a practical warning: chaga-induced kidney damage can mimic other kidney diseases, and the correct diagnosis depends on a clinician thinking to ask about mushroom supplement use.
The Complete Human Safety Literature
Three Cases, Three Different Stories
These three case reports are the entire published record of chaga harm in humans. They are usually summarized as one finding, but they differ in dose, duration, co-exposure, and outcome, and only one measured the product the patient actually consumed. Read together they support a real mechanism and a real risk; they do not support a dose threshold or an incidence estimate.
Kikuchi et al. (2014)
Clinical Nephrology
Patient
72-year-old woman
Exposure
4-5 teaspoons powder/day
6 months
Context
Taken after liver cancer diagnosis and hepatectomy
Biopsy
Diffuse tubular atrophy, interstitial fibrosis, oxalate crystals in tubular lumina and urinary sediment
Oxalate measured?
Product not analyzed
Lee et al. (2020)
J Korean Medical Science
Patient
49-year-old man
Exposure
~2x usual dietary oxalate for 4 years, ~5x in final year
~5 years
Context
Taken for intractable atopic dermatitis
Biopsy
Chronic tubulointerstitial nephritis with oxalate crystal deposits
Oxalate measured?
14.2 g oxalate/100 g measured in the retained powder
Kwon et al. (2022)
Medicine
Patient
69-year-old man
Exposure
10-15 g powder/day
3 months
Context
Acute kidney injury presenting as nephrotic syndrome
Also taking vitamin C 500 mg/day, an oxalate precursor
Biopsy
Focal acute tubular injury, calcium oxalate crystals, podocyte foot process effacement; minimal change disease
Oxalate measured?
Product not analyzed
Read it this way: the mechanism is consistent across all three, which is what makes the causal story credible. Everything else varies. Duration ranges from 3 months to 5 years, one patient had a second oxalate source (vitamin C), only one product was ever chemically analyzed, and one of the three fully recovered. That variability is why no safe dose can be inferred from this literature in either direction — it is too small and too heterogeneous to establish a threshold or to reassure.
Sources: Kikuchi et al. (2014), Clinical Nephrology 81(6):440-4; Lee et al. (2020), Journal of Korean Medical Science 35(19):e122; Kwon et al. (2022), Medicine 101(10):e28997.
Renal
CriticalSustained high-dose chaga powder has caused biopsy-confirmed kidney injury in humans
Concern
All three published cases involved daily chaga powder over months to years and ended in dialysis. One patient progressed to end-stage renal disease, one was started on hemodialysis with no recovery reported, and one recovered. The mechanism, oxalate crystal deposition in renal tubules, is consistent across all three biopsies and is driven by chaga's oxalate density, measured at 14.2 g per 100 g in the one product analyzed.
What the research says
Incidence is unknown and cannot be estimated from three case reports; chaga is consumed widely and these cases are published because they are unusual. But there is no established safe dose, no toxicology study, no RCT, and no oxalate labeling on commercial products, so exposure cannot be calculated even by a careful consumer.
Particularly relevant for: Highest theoretical risk: existing kidney disease, history of kidney stones, older adults with reduced renal reserve, and anyone also taking high-dose vitamin C, which the body metabolizes to oxalate.
What to do
If you use chaga daily and long-term, tell your physician and ask whether kidney function monitoring is warranted. Seek medical attention for unexplained swelling, reduced urine output, foamy urine, or fatigue. This article is not medical advice.
Kikuchi et al. (2014), Clin Nephrol; Lee et al. (2020), J Korean Med Sci; Kwon et al. (2022), Medicine
What the Preclinical Studies Actually Tested (and What They Did Not)
Chaga is frequently described as having a reassuring animal safety record. That description does not survive contact with the studies themselves.
The paper most often cited for chaga's safety is Mishra et al. (2012), which administered an aqueous extract of Inonotus obliquus orally to mice in a dextran sulfate sodium-induced colitis model.[4] The extract suppressed edema, mucosal damage, and crypt loss, and reduced iNOS, myeloperoxidase, and pro-inflammatory cytokine expression in colon tissue. It is a well-conducted study, and it is genuine evidence of an anti-inflammatory effect at colorectal sites.
It is not evidence of kidney safety. The design was two doses (50 and 100 mg/kg body weight) in female C57BL/6 mice over a 7-day DSS exposure, with outcomes measured in colon tissue. No renal or hepatic toxicity endpoints were assessed. Nothing in the study speaks to what happens to a kidney after months or years of oxalate loading, because the study neither ran that long nor looked at that organ.
The same caution applies to the cell studies. Park et al. (2004) pretreated human lymphocytes with aqueous chaga extract at 10 to 500 µg/mL and then challenged them with hydrogen peroxide, finding over 40% less DNA fragmentation on comet assay compared to the positive control.[5] That is a real antioxidant protective effect against an induced oxidative stress; it is not a toxicity screen. Kim et al. (2007) showed that an ethanol extract of I. obliquus inhibited lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells.[6] These studies establish that chaga's bioactive compounds have genuine pharmacological activity in cells. None of them were designed to assess chronic safety, none used the whole powdered product that the human cases involved, and the extracts differ from each other in solvent and therefore in composition.
So the apparent disconnect between "animal safety data" and human case reports is largely an artifact. There is no chaga toxicology literature to be in conflict with the case reports. There is a preclinical efficacy literature that never measured the endpoint in question, and three human cases that did. For the broader pharmacological profile, see chaga tea vs. tincture vs. capsule: best forms for bioactives.
Product Variability: Not All Chaga Is Equal
Windsor et al. (2025) applied a battery of analytical techniques (HPTLC, LC-ELSD, LC-PDA/DAD, LC-QToF-MS, NMR, UV-Vis, and iodine-starch assays) to commercial chaga dietary supplements, and the finding is more unsettling than simple batch variation.[7] Many North American products sold as chaga are not wildcrafted chaga canker at all. They are I. obliquus mycelium grown on fermented grain, and the grain comes with the product. Iodine-starch assays and β-glucan quantification confirmed a starch-rich composition in the fermented-grain products and the absence of that starch in authentic chaga canker. Authentic canker contained the triterpenoids inotodiol and trametenolic acid plus phenolics such as osmundacetone, while melanin absorbance at 500 nm further separated genuine canker from grain products. NMR fingerprinting and LC-QToF-MS metabolomics showed what the authors call stark compositional deviations between the three material types.
Kim et al. (2020) adds a second axis of variation within genuine chaga: which part of the fungus is used.[8] Analyzing inner and outer portions of I. obliquus by HPLC and LC-ESI-MS, they found inotodiol and trametenolic acid were the major triterpenoids in both, but at significantly higher concentrations in the outer part (inotodiol 194.1 mg/g outer vs 153.9 mg/g inner). Lazic et al. (2024) adds a third: extraction method.[9] Comparing subcritical water, microwave-assisted, and ultrasonic-assisted extraction on chaga from Serbia and Mongolia, subcritical water extraction produced significantly higher yield, total polysaccharide, and glucan content than any other technique, while microwave extraction with 50% ethanol gave the highest total phenols.
The safety implication is a gap rather than a finding, and it should be stated as such. Every one of these three papers measured the compounds the industry considers desirable: triterpenoids, glucans, phenolics. None of them measured oxalate. So while it is reasonable to expect that oxalate content also varies by source material, mushroom part, and preparation, that expectation is an inference, not a measurement. What is documented is that chaga products differ enormously in composition and that some are not chaga. What is not documented is how much oxalate any given product on a shelf contains. Without standardized oxalate testing and labeling, a consumer cannot calculate their exposure even in principle. For a guide to dosing, see chaga dosage guide: how much should you take?.
The Comprehensive Reviews: Benefits and Risks Together
Fordjour et al. (2023) published a wide-ranging review covering chaga's ethnobotany, mycochemistry, pharmacology, traditional therapeutic and cosmetic uses, and prospective agricultural applications.[10] It catalogues secondary metabolites including steroids and terpenoids, and documents antioxidant, anti-inflammatory, antiviral, and antitumor bioactivity. The review's framing is one of untapped potential: it argues chaga's benefits remain underexploited because its mycochemical composition is poorly understood, and it calls for expansion into pharmaceutical, food, cosmetic, and agricultural applications.
Ern et al. (2024) reviewed the therapeutic properties of I. obliquus and states that modern research provides "scientific evidence of the therapeutic properties" of its extracts, listing anti-inflammatory, antioxidant, anticancer, anti-diabetic, anti-obesity, hepatoprotective, renoprotective, anti-fatigue, antibacterial, and antiviral activities, and attributing them to polysaccharides, triterpenoids, polyphenols, and lignin metabolites.[11]
That list is worth pausing on, because it includes renoprotective. The preclinical literature contains signals that chaga protects the kidney. The clinical literature contains three reports of chaga damaging the kidney. These are not strictly contradictory (a compound can be protective in a model of acutely induced injury and harmful as a chronic oxalate load, and dose, duration, and preparation differ enormously between the two settings), but the juxtaposition is the clearest illustration available of why preclinical activity does not transfer into a human safety claim.
Evidence Asymmetry
The Benefits Are Studied in Cells. The Harms Happened to People.
Chaga’s benefit evidence and its harm evidence do not sit at the same level of the evidence hierarchy, which is why comparing them directly is misleading. Benefit claims rest on cells and a short mouse study. Harm evidence comes from human biopsies. And in the rungs where benefit evidence exists, nobody checked for harm at all.
Evidence for benefit
Evidence for harm
Human RCT
Strongest
None
No randomized controlled trial of chaga exists
None
No randomized controlled trial of chaga exists
Human clinical
Real-world outcomes
None
No human clinical benefit reported
Evidence
Three biopsy-confirmed oxalate nephropathy cases: Kikuchi 2014, Lee 2020, Kwon 2022
Animal
Indicative
Evidence
Mishra 2012: aqueous extract reduced colitis inflammation in mice (50/100 mg/kg, 7 days)
Never measured
Not assessed. Mishra measured colon endpoints only; no renal or hepatic toxicology was performed
Cell / in vitro
Mechanistic only
Evidence
Park 2004 (DNA protection in lymphocytes), Kim 2007 (anti-inflammatory in macrophages), Kim 2020 (anti-proliferative triterpenoids)
Never measured
Not assessed in the cited literature
Read it this way: the amber cells are the ones that get misread. “No toxicity reported” in a 7-day colitis study means the kidneys were never examined, not that they were examined and found healthy. Absence of measurement is not evidence of safety. Meanwhile the strongest rung is empty on both sides: there is no randomized trial showing chaga helps, and none showing it is safe.
Sources: Kikuchi et al. (2014), Clin Nephrol; Lee et al. (2020), J Korean Med Sci; Kwon et al. (2022), Medicine; Mishra et al. (2012), J Ethnopharmacol; Park et al. (2004), BioFactors; Kim et al. (2007), J Med Food; Kim et al. (2020), Molecules.
This asymmetry is the central challenge of the chaga safety question. The evidence for benefit is entirely preclinical: cells and animals, short exposures, isolated and solvent-specific extracts. The evidence for harm is human and clinical. One person reached end-stage renal disease, a second was started on hemodialysis, and a third recovered only after dialysis and high-dose steroids, while zero randomized controlled trials have demonstrated clinical benefit in humans at any dose. This does not establish that chaga is more harmful than beneficial. Three case reports drawn from a large global consumer population cannot estimate incidence, and case reports get published precisely because they are unusual. What it does establish is an evidentiary imbalance: the harm has been observed in people, and the benefit has not. For context on chaga's interactions with medications, see chaga and blood thinners: drug interaction warnings.
What the Evidence Supports and What It Does Not
| Question | Evidence | Confidence |
|---|---|---|
| Can long-term chaga cause kidney damage? | Yes: 3 published case reports of biopsy-confirmed oxalate nephropathy | Moderate |
| How often does it happen? | Unknown: case reports cannot establish incidence, and no surveillance data exist | None |
| Is the risk dose-dependent? | Plausible: all cases involved grams-per-day powder over months to years, but no dose-response data exist and no toxicology study has been run | Low |
| Does preparation method affect risk? | Plausible but unmeasured: no study has compared oxalate content across tea, tincture, capsule, or raw powder | Very low |
| Does chaga have beneficial properties? | Preclinical evidence for anti-inflammatory, antioxidant, and antitumor effects is substantial | Moderate (preclinical only) |
| Does chaga have proven human benefits? | No randomized controlled trial has demonstrated clinical benefit | None |
| Is there a safe long-term dose? | No human trial has established one | None |
| Do all chaga products carry the same risk? | No: composition varies by source, mushroom part, and extraction, and some products are fermented grain rather than chaga | Low to moderate |
| Is oxalate content labeled or standardized? | No: no cited analysis measured oxalate across commercial products | None |
The Bottom Line
Three published case reports document biopsy-confirmed oxalate nephropathy from chaga consumption. One chaga powder was measured at 14.2 g oxalate per 100 g, on the order of 15 to 25 times the oxalate density of spinach. One patient reached end-stage renal disease and one was started on hemodialysis; a third, who was also taking 500 mg of vitamin C daily, recovered fully after dialysis and steroids. No toxicology study has tested chaga for renal toxicity, and the animal work commonly cited as reassuring was a 7-day colitis efficacy study that never examined the kidneys. No human RCT has tested safety or benefit at any dose. Composition varies by source, mushroom part, and extraction method, and some North American supplements are fermented grain rather than chaga. No study has measured oxalate across commercial products, so consumers cannot assess their exposure.
Frequently Asked Questions
Sources & References
- 1RTHM-00775·Kwon, Ohyun et al. (2022). “Chaga mushroom-induced oxalate nephropathy that clinically manifested as nephrotic syndrome: A case report..” Medicine.Study breakdown →PubMed →↩
- 2RTHM-00329·Kikuchi, Yuko et al. (2014). “Chaga mushroom-induced oxalate nephropathy..” Clinical nephrology.Study breakdown →PubMed →↩
- 3RTHM-00630·Lee, Sua et al. (2020). “Development of End Stage Renal Disease after Long-Term Ingestion of Chaga Mushroom: Case Report and Review of Literature..” Journal of Korean medical science.Study breakdown →PubMed →↩
- 4RTHM-00258·Mishra, Siddhartha Kumar et al. (2012). “Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
- 5RTHM-00076·Park, Yoo Kyoung et al. (2004). “Chaga mushroom extract inhibits oxidative DNA damage in human lymphocytes as assessed by comet assay..” BioFactors (Oxford.Study breakdown →PubMed →↩
- 6RTHM-00117·Kim, Ho-Gyoung et al. (2007). “Ethanol extract of Inonotus obliquus inhibits lipopolysaccharide-induced inflammation in RAW 264.7 macrophage cells..” Journal of medicinal food.Study breakdown →PubMed →↩
- 7RTHM-02209·Windsor, Coleton et al. (2025). “What This 2025 Chaga Supplement Authentication Study Actually Found.” International journal of molecular sciences.Study breakdown →PubMed →↩
- 8RTHM-01218·Kim, Jaecheol et al. (2020). “Composition of Triterpenoids in Inonotus obliquus and Their Anti-Proliferative Activity on Cancer Cell Lines..” Molecules (Basel.Study breakdown →PubMed →↩
- 9RTHM-00888·Lazić, Vesna et al. (2024). “The Effect of Green Extraction Technologies on the Chemical Composition of Medicinal Chaga Mushroom Extracts..” Journal of fungi (Basel.Study breakdown →PubMed →↩
- 10RTHM-01694·Fordjour, Eric et al. (2023). “Chaga mushroom: a super-fungus with countless facets and untapped potential..” Frontiers in pharmacology.Study breakdown →PubMed →↩
- 11RTHM-01886·Ern, Phoebe Tee Yon et al. (2024). “Chaga Therapeutic Properties: What This 2024 Review Actually Shows.” Mycology.Study breakdown →PubMed →↩